NBE-Therapeutics

NBE-Therapeutics is a private, clinical-stage biotech developing a novel platform for antibody-drug conjugates (ADCs) targeting solid tumors. Its core innovation combines proprietary conjugation technology with a novel anthracycline-based payload (PNU) to create ADCs intended to be both highly potent and immunogenic. The company has built a pipeline of ADC candidates advancing towards clinical trials, aiming to address the need for more selective and effective cancer therapies. Its strategic location in Basel, a major European biopharma hub, supports its research and potential partnership activities.

Proprietary next-generation antibody-drug conjugate (ADC) platform featuring a novel conjugation technology, a proprietary immunogenic anthracycline payload (PNU), and an integrated antibody discovery engine (AnTiBody Discovery IADC) designed to create potent, targeted therapies for solid tumors with a long-lasting immune-oncology effect.

The ADC field is highly competitive, dominated by large pharmaceutical companies and numerous biotech innovators. NBE competes on the basis of its proprietary, integrated platform—particularly its novel immunogenic anthracycline payload—aiming to create best-in-class therapies for solid tumors where current ADCs have limitations. Success requires demonstrating clear differentiation in potency, safety, or mechanism.